Affordable Access

deepdyve-link
Publisher Website

Evolución de la utilización de antidepresivos, ansiolíticos e hipnóticos en la Comunitat Valenciana. Período 2000-2010

Authors
  • Sempere Verdú, Ermengol
  • Salazar Fraile, José
  • Palop Larrea, Vicente
  • Vicens Caldentey, Caterina1, 2, 3, 4
  • 1 Médico de familia, Centro de Salud de Paterna
  • 2 Psiquiatra, Centro de Salud de Paterna
  • 3 Médico de familia, Subdirección Asistencial Departamento de Salud de la Ribera
  • 4 Médico de familia, Centro de Salud Son Vileta
Type
Published Article
Journal
Atencion Primaria
Publication Date
Jan 01, 2013
Accepted Date
Nov 24, 2013
Identifiers
DOI: 10.1016/j.aprim.2013.11.006
Source
Elsevier
Keywords
License
Unknown

Abstract

ObjectiveTo describe the evolution in the use of antidepressants (AD), anxiolytics (A) and hypnotics (H) in the Comunitat Valenciana (CV) between 2000 and 2010, their expenditure, and the cost of the defined daily dose (DDD). DesignRetrospective observational study. SettingPrescriptions covered by the health public service of the CV during the period 2000-2010. MeasurementsConsumption of the therapeutic groups N06A (antidepressants), N05B (anxiolytics) and N05C (hypnotics) from the pharmacy database of the public Valencian Health Agency measured in defined daily dose per 1.000 inhabitants. ResultsDuring the period of study the use of AD increased by 81.2% and A and H, 11.7%. Selective serotonin reuptake inhibitors were the most prescribed AD and Selective serotonin and norepinephrine reuptake inhibitors experienced the higher rise (386.8%). The increase of escitalopram was 1.013%. Lorazepam, alprazolam and diazepam, accounted for the 80.4% of the anxyolitics, and lormetazepam and zolpidem the 88.7% of the hypnotics. The expenditure rise of AD was by 78.2% and that of the A and H was 14.5%; the cost of the DDD of both decreased by 29%. ConclusionsAntidepressant utilization has experienced a remarkable rise between 2000 and 2010 while that of A and H has been mild even though they are still more consumed than AD. In spite of the reduction of the DDD cost in both therapeutic groups, the whole expenditure on AD in the CV is still growing.

Report this publication

Statistics

Seen <100 times